Estradiol II Elecsys and cobas e analyzers REF 03000079 190; M 6.5mL, R1 8 mL, R2 8 mL, IVD, For USA: CONTENT M Streptavidin-coated microparticles 0.72 mg/mL; R1 Biotinylated polyclonal anti-estradiol antibody (rabbit) 45 ng/mL; Mesterolone 130 ng/mL; R2 Estradiol derivative, labeled with ruthenium complex 2.75 ng/mL Product Usage: Immunoassay for the in vitro quantitative determination of estradiol in human serum and plasma. The electrochemiluminescence immunoassay ECLIA is intended for use on Elecsys and cobas e immunoassay analyzers.
Published April 6, 2016 · Recall initiated: March 7, 2016
Summary
FDA records medical device Class II recall Z-1277-2016, published April 6, 2016 and initiated March 7, 2016. Recalling firm: Roche Diagnostics Operations, Inc.; Status: Terminated; Reported quantity: 102,312; Lot: Part Number Elecsys Estradiol II : 03000079190; all lot numbers are affected. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Due to the risk of a recently identified cross reactivity, the Elecsys Estradiol assay should not be used when monitoring patient being treated with fulvestrant. Customers should be informed that fulvestrant will increase the apparent concentration of estradiol in women being treated with this drug. If treatment with fulvestrant has been altered or discontinued as a result of falsely elevated e
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Roche Diagnostics Operations, Inc.
- Distributor
- US Nationwide Distribution including Puerto Rico.
- Lot
- Part Number Elecsys Estradiol II : 03000079190; all lot numbers are affected.
- Risk classification
- Class II
- Area (FDA)
- device
- Country
- United States
Related recalls
- FDAcobas HCYS, Homocysteine Enzymatic Assay, Material Number REF 06542921190, for use on cobas c 701/702, inNovember 27, 2024
- FDACreatine Kinase (CK) used on cobas c 311/501/502 and COBAS INTEGRA 400 plus-In vitro test for the quantitativeOctober 2, 2024
- FDAAlbumin Gen.2, Catalog 05166861190October 21, 2020
- FDAElecsys Anti-HAV IgM assay-for the in vitro qualitative detection of IgM antibodies to hepatitis A virusDecember 18, 2019
- FDAMedtronic, Model 8781 Ascenda" Intrathecal Catheter kit, Rx Only, Sterile Ethylene Oxide.April 6, 2016
- FDACios Alpha, mobile X-ray systemApril 6, 2016
Questions about this recall
Was Estradiol II Elecsys and cobas e analyzers REF 03000079 190; M 6.5mL, R1 8 mL, R2 8 mL, IVD, For USA: CONTENT M Streptavidin-coated microparticles 0.72 mg/mL; R1 Biotinylated polyclonal anti-estradiol antibody (rabbit) 45 ng/mL; Mesterolone 130 ng/mL; R2 Estradiol derivative, labeled with ruthenium complex 2.75 ng/mL Product Usage: Immunoassay for the in vitro quantitative determination of estradiol in human serum and plasma. The electrochemiluminescence immunoassay ECLIA is intended for use on Elecsys and cobas e immunoassay analyzers. recalled?
Yes. FDA published recall Z-1277-2016 on April 6, 2016. Reported hazard: Due to the risk of a recently identified cross reactivity, the Elecsys Estradiol assay should not be used when monitoring patient being treated with fulvestrant. Customers should be informed that fulvestrant will increase the apparent concentration of estradiol in women being treated with this drug. If treatment with fulvestrant has been altered or discontinued as a result of falsely elevated e
What should I do if I have this product?
Voluntary: Firm initiated · Letter